**Core Concept**
Rotigotine is a dopamine agonist used in the treatment of Parkinson's disease, restless legs syndrome, and moderate-to-severe primary restless legs syndrome. It acts by stimulating dopamine receptors in the brain, mimicking the action of dopamine, which is deficient in Parkinson's disease.

**Why the Correct Answer is Right**
Rotigotine binds to dopamine D1, D2, D3, D4, and D5 receptors, exerting its therapeutic effects. This action leads to improved motor function, reduced tremors, and improved sleep quality in patients with Parkinson's disease. The transdermal delivery system of rotigotine allows for continuous release of the drug, providing a stable plasma concentration and minimizing fluctuations in motor symptoms.

**Why Each Wrong Option is Incorrect**
**Option A:** is incorrect because it does not accurately describe the primary mechanism of action of rotigotine.
**Option B:** is incorrect because while rotigotine does have some effect on dopamine receptors, it is not primarily classified as an MAO-B inhibitor.
**Option C:** is incorrect because rotigotine is not an anticholinergic agent, which is a different class of drugs used in the treatment of Parkinson's disease.

**Clinical Pearl / High-Yield Fact**
Rotigotine is the only dopamine agonist available in a transdermal patch formulation, which allows for once-daily dosing and improved patient compliance.

**Correct Answer:** C. A dopamine agonist.